title: Prophylactic use of octreotide for asparaginase-induced acute pancreatitis.
abstract: In the present study, we sought to evaluate the prophylactic use of octreotide for asparaginase-induced acute pancreatitis. We reviewed the medical records of seven patients in two institutions who received prophylactic octreotide for re-administration of asparaginase after asparaginase-induced acute pancreatitis. Three patients completed asparaginase treatment without developing pancreatitis, and four experienced recurrence of pancreatitis. A literature search using PubMed identified four additional patients in whom asparaginase was successfully re-administered with octreotide. Prophylactic use of octreotide may, thus, be warranted for patients who would benefit from re-administration of asparaginase for cancer treatment; however, careful observation is needed to monitor for breakthrough recurrence of pancreatitis.
authors.affiliation: Department of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan. sachi@juntendo.ac.jp.
authors.forename: Sachi
authors.identifier: http://orcid.org/0000-0003-0119-1796
authors.initials: S
authors.lastname: Sakaguchi
authors.affiliation: Department of Pediatric Hematology and Oncology, Okinawa Prefectural Nanbu Medical Center Children's Medical Center, Okinawa, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Higa
authors.affiliation: Department of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan.
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Suzuki
authors.affiliation: Department of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan.
authors.forename: Junya
authors.initials: J
authors.lastname: Fujimura
authors.affiliation: Department of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Shimizu
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D015282:Octreotide / Q000008:administration & dosage*; D010195:Pancreatitis / Q000139:chemically induced* / Q000517:prevention & control*; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D005765:Gastrointestinal Agents; D001215:Asparaginase; D015282:Octreotide
keywords: Acute lymphoblastic leukemia; Acute pancreatitis; Asparaginase; Octreotide; Prophylaxis